Nautilus Biotechnolgy
NAUT
71 hedge funds and large institutions have $43.3M invested in Nautilus Biotechnolgy in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 28 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.39% less ownership
Funds ownership: 49.76% → 47.37% (-2.4%)
19% less funds holding
Funds holding: 88 → 71 (-17)
20% less capital invested
Capital invested by funds: $54M → $43.3M (-$10.7M)
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$727K |
| 2 |
Corient Private Wealth
Miami,
Florida
|
+$293K |
| 3 |
Renaissance Technologies
New York
|
+$240K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$169K |
| 5 |
Jane Street
New York
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.63M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$923K |
| 3 |
State Street
Boston,
Massachusetts
|
-$548K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$449K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$257K |
NAUT Hedge Fund Activity: Q2 2025 in Review
71 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q2 2025, worth a combined $43.3M — down 20% from $54M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of NAUT and 12 opened new positions — a net loss of 16 holders — while 17 trimmed existing stakes and 25 added.
The largest buyer was Millennium Management, adding an estimated $727K. The largest seller was BlackRock, cutting an estimated $1.63M.
- 71 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q2 2025, down from 88 in Q1 2025.
- Funds reported $43.3M of Nautilus Biotechnolgy stock for Q2 2025, down 20% quarter-over-quarter.
- 12 funds opened new Nautilus Biotechnolgy positions in Q2 2025 and 28 closed out, a net change of -16 holders.
- The largest Nautilus Biotechnolgy buyer in Q2 2025 was Millennium Management, an estimated $727K added.
- The largest Nautilus Biotechnolgy seller in Q2 2025 was BlackRock, an estimated $1.63M sold.
Based on aggregated 13F filings for Q2 2025.